authors Rusthoven, James Quirt, IC Iscoe, NA McCulloch, PB James, KW Lohmann, RC Jensen, J BurdetteRadoux, S Bodurtha, AJ Silver, HKB Verma, S Armitage, GR Zee, B Bennett, K Hedley, D Fine, S Myers, R King, M Mertens, W Taylor, M Cano, P Malik, S Vergidis, D Shore, S Dudgeon, D Smylie, M Wilson, K Knowling, M Samosh, M Giesbrecht, J Huan, S Skillings, J Gregg, R Belanger, K Pollak, M Latreille, J Batist, G Boos, G Gruner, P Hings, I Loutfi, A Thirlwell, M Trudeau, M Jolivit, J Ayoub, J Charpentier, D Clement, S Yelle, L Belanger, D Shibata, H
has subject area 1103 Clinical Sciences (FoR) 1112 Oncology and Carcinogenesis (FoR) Adult (MeSH) Aged (MeSH) Antineoplastic Combined Chemotherapy Protocols (MeSH) Carmustine (MeSH) Cisplatin (MeSH) Dacarbazine (MeSH) Disease-Free Survival (MeSH) Double-Blind Method (MeSH) Female (MeSH) Humans (MeSH) Male (MeSH) Melanoma (MeSH) Middle Aged (MeSH) Oncology & Carcinogenesis (Science Metrix) Skin Neoplasms (MeSH) Survival Rate (MeSH) Tamoxifen (MeSH)
keywords CLINICAL-TRIALS COMBINATION CHEMOTHERAPY COOPERATIVE GROUP DISSEMINATED MALIGNANT-MELANOMA DTIC NSC-45388 HIGH-DOSE CISPLATIN Life Sciences & Biomedicine MULTIPLE TESTING PROCEDURE Oncology PHASE-II SOUTHWEST-ONCOLOGY-GROUP Science & Technology THERAPY
